Cantor Fitzgerald raised the firm’s price target on Alnylam (ALNY) to $450 from $325 and keeps an Overweight rating on the shares. Focus is on Amvuttra’s Q3 results after a strong $150M debut in ATTR-CM last quarter, with expectations now above $300M, the analyst tells investors in a research note. Alnylam continues to execute well on the cardiomyopathy launch, and signs point to sustained commercial momentum through the second half of 2025, the firm says.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY: